CENTR Brands - CEO, Arjan Chima
CEO, Arjan Chima
Source: LinkedIn
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • CENTR Brands Corp. (CNTR) announced its gross sales for its fourth fiscal quarter ending May 31, 2022
  • Total gross sales during the period were approximately $625,094 as compared to approximately $99,436 for the fourth quarter ending May 31, 2021
  • CENTR will launch various brand awareness initiatives, including activation and experiential events throughout California this summer
  • CENTR Brands is one of North America’s leading functional beverage companies
  • CENTR (CNTR) opened trading at C$0.46

CENTR Brands Corp. (CNTR) announced its gross sales for its fourth fiscal quarter ending May 31, 2022.

Total gross sales during the period were approximately $625,094 as compared to approximately $99,436 for the fourth quarter ending May 31, 2021.

The company’s strong results are a reflection of its growing wellness product portfolio, which now includes ready-to-mix CENTR Instant powders. CENTR’s quarter over quarter growth also reflects strong load-in purchasing activity by the company’s distributors as they prepare inventory for the summer months.

CENTR’s CEO Arjan Chima, commented on the results.

“At the company’s core, CENTR is a brand business focused on delivering innovative products to its consumer base in the functional health and wellness category. We are proud of the company’s continued growth.” 

Throughout the summer months, CENTR will launch various brand awareness initiatives, including activation and experiential events throughout California. Thousands of American consumers will have an opportunity to engage with the brand and try CENTR’s products at these events, and in conjunction with influencer partnerships and related media campaigns in development.

CENTR Brands is one of North America’s leading functional beverage companies.

CENTR (CNTR) opened trading at C$0.46.

More From The Market Herald

" Update from Revive Therapeutics (CSE:RVV) on Phase 3 clinical trial for Bucillamine in COVID-19

Revive Therapeutics (RVV) has provided an update on the company’s U.S. Food & Drug Administration (FDA) Phase 3 clinical trial.

" EnWave (TSXV:ENW) signs technology evaluation agreement with Canadian cannabis cultivator

EnWave Corporation (ENW) has signed an agreement with a Canadian cannabis company to use its 10kW Radiant Energy Vacuum (REV) technology.

" Core One Labs (CSE:COOL) subsidiary Vocan successfully converts Psilocin precursor into Psilocybin

Core One Labs (CSE:COOL) subsidiary Vocan Biotechnologies has converted psilocin developed by Awakened Biosciences into viable API psilocybin.